WHAT IS CANNABIDIVARIC ACID (CBDVA)?
Like any other Cannibinoids, Cannabidivarinic Acid (CBDVA) is a non-psychoactive Cannabinoid found in Cannabis being the precursor of Cannabidivarin (CBDV) having some anti-inflammatory properties. By its anti-inflammatory properties, it means it is capable of remedying pain by reducing inflammation as opposed to opioids, which affect the central nervous system to block pain signaling to the brain. This implies, it can work as analgesics to reduce pain and inflammation or swelling.
Nothing or little is known of when and how CBDVA was identified but insights can be drawn from when its precursor was first identified. Although first isolated in 1969 by Vollner, et al., Cannabidivarin (CBDV) was probably first reported in a benzene extract from a Thai cannabis variety referred to as “Meao”.
It’s important to state that Cannabinoids are derived in plants from the cannabis family basically hemp and marijuana. Cannabinoids of which Cannabidivarinic acid is one, interacts with the available Cannabinoids in the human body system which is called endocannabinoids to regulate the body system and functions. The prefix “Endo” at the beginning of the word is a pointer that it is within the body. Thus, endocannabinoids are the Cannabinoids with the human body that helps regulate the systems that control pain, appetite and neurological functions such as cognitive function, cranial nerves, motor strength, sensation, reflexes, coordination, and gait.
More so, in action, it enhances functions including self-monitoring, organization, motor planning and initiation (expression language), attention and concentration, mental inflexibility, behavioral inhibition, personality and awareness of abilities and limitations to mention but a few.
Only very little is known of the Cannabidivarinic Acid (CBDVA) just like the Cannabidivarin (CBDV) as it has only received little attention and studies as at the moment although, it is expected to become a more interesting area of interest in the nearest future. However, despite that only little can be said of it, it is evident that CBDVA possesses properties and potential benefits though one may not be able to emphatically establish them now.
HOW IT WORKS
Anderson, et al in their study on the effect of cannabidiolic acids in a Mouse Model of Dravet Syndrome, recorded of Cannabidivarinic Acid (CBDVA) that rapid absorption of CBDVA was observed following intraperitoneal (i.p.) administration with a plasma tmax of 15 min and a t1/2 of 49 min. Absorption into the brain was slightly delayed, as the tmax was 30 min; however, the Cmax was quite low and elimination was rapid (t1/2 19 min). At 60 min, CBDVA was detected in brain tissue but was below the limit of quantification (LOQ), so a value of 1/2 LOQ (0.25 ng/mg brain) was used. Elimination was complete by 90 min. The brain−plasma ratio (0.02) suggests CBDVA exhibits poor brain penetration. The neutral form of CBDVA, cannabidivarin (CBDV), was not detected in the brain or plasma following injection of CBDVA, suggesting there is no significant decarboxylation of CBDVA to CBDV in vivo following i.p. injection. This study suggests that Cannabidivarinic Acid being a cannabidiolic acids (CBDA), can serve as anticonvulsant against HyperthermiaInduced Seizures.
That little is known of the Cannabidivarinic Acid (CBDVA) is not an indication that it is without therapeutic benefits. Since it is a cannabinoid and Cannabinoids are known for easing anxiety, slow tumor growth, eradication of cancer cells, reducing symptoms of nausea and vomiting, stimulating appetites, muscle relaxation, and reducing seizure activity.
Specifically, the Cannabidivarinic Acid (CBDVA) has as its capacity anti-inflammatory benefits that can ease arthritis pain, swelling from an injury, and constant pain from chronic conditions.
CBDVA has no capacity to induce a “high” when used.
- Lyndsey L. Anderson, Ivan K. Low, Samuel D. Banister, and Jonathon C. Arnold, “Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome” Journal of Natural Products.
- Shoyama, Y., Hirano, H., Makino, H., Umekita, N., Nishioka, I., 1977. Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid, from Thai cannabis, FMeao variant_. Chemical and Pharmaceutical Bulletin 25 (9), 2306–2311.
- Vollner L, Bieniek D, Korte F. 1969. Hashish. XX. Cannabidivarin, a new hashish constituent. Tetrahedron Letters 3:145–147 DOI 10.1016/S0040-4039(01)87494-3. Amada et al. (2013), PeerJ, DOI 10.7717/peerj.2141